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ARTICLE
Structural insights into substrate recognition
by the SOCS2 E3 ubiquitin ligase
Wei-Wei Kung1,2, Sarath Ramachandran1,2, Nikolai Makukhin1,2, Elvira Bruno1 & Alessio Ciulli 1
The suppressor of cytokine signaling 2 (SOCS2) acts as substrate recognition subunit of a
Cullin5 E3 ubiquitin ligase complex. SOCS2 binds to phosphotyrosine-modiﬁed epitopes as
degrons for ubiquitination and proteasomal degradation, yet the molecular basis of substrate
recognition has remained elusive. Here, we report co-crystal structures of SOCS2-ElonginB-
ElonginC in complex with phosphorylated peptides from substrates growth hormone receptor
(GHR-pY595) and erythropoietin receptor (EpoR-pY426) at 1.98 Å and 2.69 Å, respectively.
Both peptides bind in an extended conformation recapitulating the canonical SH2 domain-pY
pose, but capture different conformations of the EF loop via speciﬁc hydrophobic interactions.
The ﬂexible BG loop is fully deﬁned in the electron density, and does not contact the sub-
strate degron directly. Cancer-associated SNPs located around the pY pocket weaken
substrate-binding afﬁnity in biophysical assays. Our ﬁndings reveal insights into substrate
recognition and speciﬁcity by SOCS2, and provide a blueprint for small molecule
ligand design.
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Cytokines are small glycoproteins that play important rolesin the differentiation, development and function of lym-phoid and myeloid cells1. The Janus kinase (JAK)—signal
transducer and activator of transcription (STAT) signaling
pathway plays a critical role enabling cells to respond to speciﬁc
cytokines by regulating gene expression. Suppressor of cytokine
signaling (SOCS) proteins, which comprise of cytokine inducible
SH2-containing protein (CIS) and SOCS1–SOCS7, negatively
regulate cytokine receptors and inhibit the JAK-STAT signaling
pathway2.
SOCS proteins share a conserved domain architecture com-
prising of an N-terminal extended SH2 subdomain (ESS) that
functions as a bridge at the interface between the SH2 domain and
the SOCS box enabling ubiquitination of captured substrate3–5,
followed by a central Src-homology 2 (SH2) domain that recog-
nizes a phosphotyrosine (pY) containing sequence6, and a C-
terminal SOCS box that interacts with the adapter ElonginB-
ElonginC complex (EloBC)7–9. All SOCS proteins bind to EloBC
and recruit Cullin5 with high speciﬁcity, forming different SOCS-
EloBC-Cullin5-Rbx2 (CRL5SOCS) E3 ligases that catalyze ubiquitin
transfer and subsequent proteasomal degradation of speciﬁc
substrates, as a mechanism to regulate diverse biological pro-
cesses10–13. SOCS proteins serve as substrate recognition modules
that impart substrate speciﬁcity to each CRL5SOCS E3 complex.
Expression of SOCS proteins is induced by cytokine stimula-
tion. Upon cytokine binding, the oligomerized receptors activate
the JAK family kinases that phosphorylate speciﬁc tyrosine resi-
dues on the receptor, including the docking sites for the STAT
proteins. The docked STAT proteins are sequentially phos-
phorylated, they dimerize and translocate into the nucleus,
initiating gene transcription of several downstream proteins
including the SOCS proteins. SOCS proteins suppress the JAK-
STAT pathway via three distinct but often concomitant
mechanisms: (1) KIR mediated direct JAK inhibition3,14; (2)
Blocking STAT activation by competing for receptor pY sites15;
(3) Targeting the receptor for proteasomal degradation via SOCS
E3 ligase activity16,17. Some of the SOCS-substrate interactions
have been structurally characterized, including SOCS1-JAK18,
SOCS3-gp1304,19, SOCS3-gp130-JAK220, and SOCS6-cKit21.
SOCS2, one of the members of the SOCS family, is implicated in
disorders of the immune system, central nervous system and cancer,
and is thus emerging as a promising therapeutic target 22–25. SOCS2
has been shown as the primary suppressor of growth hormone
(GH) pathway where a gigantism phenotype was observed in a
SOCS2−/−mice26. Paradoxically, the SOCS2 overexpressed trans-
genic mice also led to the same phenotype27. Attenuation of GHR
signaling relies on two phosphorylation sites at GHR that are
recognized by SOCS216,28. The pY487 site of GHR interacts with
CRL5SOCS2 E3 ligase that targets the GHR for ubiquitination and
proteasomal degradation16. A downstream pY595 site interacts with
SOCS2, STAT5b and SHP2 (SH2 domain-containing phosphatase
2), enabling SOCS2 to inhibit the signaling by blocking this receptor
site from STAT5b15,27,29,30. Nonetheless, deletion of both sites is
required to remove the inhibitory effect of SOCS2 on the GH
signaling16,28. Analysis of the binding afﬁnity of SOCS2 for these
two phosphorylation sites of GHR reveals that the pY595 region
exhibits a higher afﬁnity towards SOCS2 (KD= 1.6 μM) compared
to the pY487 region (KD= 11.3 μM)5,31,32. An 11-mer phos-
phorylated peptide spanning the pY595 region of GHR was sufﬁ-
cient to pull down the whole CRL5SOCS2 complex from human cell
lysates31 as well as CIS, the closest homolog to SOCS2 from the
same family, which plays a role in anti-tumor immunity controlling
the differentiation of CD4 T helper cell, and the IL-2 and IL-4
response31,33. In addition to GHR, other substrates have been
identiﬁed to interact with SOCS2, including the erythropoietin
receptor (EpoR) at pY42634, the leptin receptor at pY107735, the
epidermal growth factor receptor36 and the insulin-like growth
factor-I receptor37. The ﬁrst crystal structure of SOCS2-ElonginB-
ElonginC (SBC) was reported in 200632, however the structural
basis for substrate recognition by SOCS2 has yet remained elusive.
Here, we determine the co-crystal structures of SBC in complex
with phosphorylated epitope peptides from its physiological tar-
gets GHR and EpoR. Our structures reveal the peptides are
accommodated in an extended conformation to capture speciﬁc
interactions with SOCS2. A key ﬂexible region of SOCS2, known
as the BG loop, is deﬁned in the electron density and shown not
to contact the bound substrates. Structural analyses supported by
biophysical and mutagenesis investigations identify hotspot resi-
dues on the substrate degrons and functionally elucidate disease-
relevant single nucleotide polymorphisms (SNPs) of SOCS2. Our
ﬁndings reveal fresh insights into the molecular recognition and
selectivity between SOCS2 and target substrates, and provide an
important template for future structure-guided ligand design.
Results
Crystallization of substrate-bound SOCS2. To elucidate the
molecular basis of substrate recognition by SOCS2, we subjected
the SOCS2-ElonginB-ElonginC (SBC) complex to extensive co-
crystallization trials with 11-residue phosphopeptides of either
EpoR or GHR that span the regions surrounding Tyr426 and Tyr
595 region, respectively. The afﬁnity of SBC for EpoR_pY426 (KD
of 6.9 μM) and GHR_pY595 (KD of 1.1 μM) was measured by
isothermal titration calorimetry (ITC), and found to be consistent
with the literature31,32 (Supplementary Fig. 1). Attempts to co-
crystallize wild-type SBC protein constructs31,32 with either GHR
or EpoR peptide were unsuccessful as resulting crystals only
diffracted poorly. To improve crystal quality, we engineered a
cluster of three mutations K115A/K117A/Q118A on SOCS2 that
was predicted to signiﬁcantly reduce surface conformational
entropy and thermodynamically favor crystal packing38. Crys-
tallization attempts with this new SKKQBC triple-mutant con-
struct (K115A/K117A/Q118A on SOCS2) eventually yielded
high-resolution datasets.
SBC-EpoR co-crystal structure. The structure of SBC in complex
with EpoR_pY426 peptide (SBC-EpoR) was solved and reﬁned at
2.69 Å with 19.64% Rwork and 23.51% Rfree (Table 1). The overall
subunit and domain arrangements of the SBC-EpoR structure is
consistent with those of the apo SBC structures32,39,40 (Fig. 1a).
Electron density for nine out of eleven non-terminal EpoR_pY426
residues are well deﬁned in the structure (Fig. 1b). A classic SH2
domain-pY peptide interaction is observed, where the pY residue
is anchored at the pY pocket and the ﬂanking residues are
extending across the SH2 domain. The pY residue is tightly
locked by an intricate hydrogen-bonding network formed by
residues Arg73, Ser75, Ser76, Thr83, and Arg96 of SOCS2
(Fig. 1c). Additional hydrogen bonds are formed along the
backbone of EpoR_pY426 peptide from Glu(−1) to Leu(+3) with
SOCS2 residues Thr93, Asn94, Asp107 and one structural water
(Fig. 1d). Multiple hydrophobic interactions also support the
binding of EpoR_pY426 C-terminal residues, Ile(+2), Leu(+3),
and Pro(+5) that are well accommodated within a hydrophobic
patch created by Leu95, Leu106, Ser108, Ile109, Val112, Leu116,
and Leu150 of SOCS2 (Fig. 1e).
Crystal structure of SBC-GHR. Encouraged by the success in
solving an SBC-EpoR structure, to deepen understanding of the
SOCS2 binding epitopes, we co-crystallized SBC with an 11-mer
GHR_pY595 peptide (SBC-GHR) and solved the structure at
1.98 Å resolution with 19.00% Rwork and 22.66% Rfree (Table 1).
In contrast to SBC-EpoR, which contains one protomer in the
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asymmetric unit, the SBC-GHR contains two copies of protomer.
Alignment of these two protomers via the backbone atoms of the
EloB subunit reveals a hinge motion between the SH2 domain
and the SOCS box (Supplementary Fig. 2). Such motion is a
common feature in SOCS box and F-box containing proteins and
it has been shown to be important as it facilitates accurate
orientation and positioning of a target substrate protein relative
to the multisubunit CRL complex39,41. Contrary to the SBC-EpoR
complex, which contains a single copy of peptide per SH2
domain, two copies of GHR_pY595 peptides were found binding
per SH2 domain of SOCS2 (giving a total of four copies within
the asymmetric unit). The two peptides run in an anti-parallel
direction relative to each other across the SH2 domain, with well-
deﬁned electron density surrounding them both (Fig. 2a). One of
the peptides (referred to as peptide A hereafter) binds to SH2
domain in a canonical manner, where the pY is recognized by the
positively charged pY pocket between the central β strands and
αA (Fig. 2b). In contrast, the second peptide, peptide B, has its pY
residue exposed to solvent and interacting only with His149 of
SOCS2 (Fig. 2b).
Speciﬁc interaction of the GHR_pY595 phosphopeptide. The
unusual simultaneous binding observed for the GHR substrate
peptide to SOCS2 SH2 domain is imparted mainly by the
region comprising Ser(+2) to Val(+6) from each peptide,
which pair such that they form an anti-parallel beta sheet
(Fig. 2c). Extensive hydrogen bonds are formed between the
backbone of the two peptides and backbone residues of SOCS2
and structural waters (Fig. 2c). Further hydrophobic interac-
tions appear to reinforce the binding, which impart speciﬁcity
for GHR. The Ile(+3) and Ile(+5) of peptide A and peptide B
settle in a hydrophobic patch of the SH2 domain formed by
Leu95, Leu106, Ser108, Leu116, and Leu150 (Fig. 2d). Another
hydrophobic interaction that is distinct in SBC-GHR compared
to SBC-EpoR is that formed by the side chain of Val(−3) of
peptide A, that nicely ﬁts into a hydrophobic pocket com-
prising of Thr88, Ala90, Thr93, Leu95, and Val148 from
SOCS2 (Fig. 2e). In the SBC-GHR structure, a cobalt ion is
modeled at a positive peak that disappeared only at 21 σ level
in the unbiased Fo-Fc electron density map. This cobalt ion
satisﬁes the formation of an octahedral coordination geometry
with the side chains of His(+4) of peptide B, His149 of SOCS2
and with four surrounding water molecules (Fig. 2f).
The BG loop of SOCS2 is observed in an open conformation.
SOCS2 recognizes two GHR binding sites at regions around
pY487 and pY595, respectively. We therefore hypothesized that
the two copies of the GHR peptides bound in the crystal structure
might mimic a physiological folded conformation of GHR, pre-
senting each of the phosphorylated sites bound simultaneously to
SOCS2. To test this hypothesis, we utilized an 11-residue
GHR_pY487 phosphopeptide (NIDFpYAQVSDI, KD of 2.3 μM
by ITC, Supplementary Fig. 1), mixed with the GHR_pY595
peptide and SBC in equimolar 1:1:1 ratio for co-crystallization. In
this crystal structure (hereafter referred to as SBC-GHR2), still
two copies of the GHR_pY595 peptide, but no GHR_pY487, are
observed bound, yielding a structure very similar to the previous
SBC-GHR structure (Supplementary Fig. 3). However, an
important observation in SBC-GHR2 compared to our other co-
crystal structures was that the region of SOCS2 corresponding to
residues 134–162, also called BG loop, is now fully visible in the
electron density. The BG loop connects the αB and βG strand of
an SH2 domain (Fig. 3a). The ﬁrst part of the BG loop (residues
134–148 in SOCS2) differs in length and sequence among SOCS
Table 1 Crystallographic data collection and reﬁnement statistics
SBC-EpoR SBC-GHR SBC-GHR2
PDB code 6I4X 6I5N 6I5J
Data collection
Wavelength (Å) 0.9686 0.9795 0.9686
Space group I 1 2 1 P 21 21 2 P 2 21 21
Cell dimensions
a, b, c (Å) 41.29, 56.33, 203.39 113.18, 156.76, 57.57 57.83, 113.71, 156.94
α, β, γ (°) 90.00, 91.53, 90.00 90.00, 90.00, 90.00 90.00, 90.00, 90.00
Molecules/ASU 1 2 2
Resolution 29.36–2.69 (2.82–2.69) 113.55–1.98 (2.01–1.98) 92.08–2.80 (2.95–2.80)
Rmerge (%) 10.8 (51.4) 9.4 (103.5) 19 (72.1)
<I/σ (I)> 9.6 (2.4) 17.1 (2.2) 7.3 (2.7)
Completeness (%) 93.2 (63.3) 100 (100) 100 (100)
Redundancy 4.9 (4.2) 13.3 (13.2) 7.8 (7.8)
CC1/2 0.99 (0.82) 1.0 (0.9) 0.98 (0.74)
Reﬁnement
Resolution (Å) 2.69 1.98 2.8
Unique reﬂections 12,265 (791) 72,170 (7105) 26,275 (2606)
Rwork/Rfree (%) 19.64/23.51 19.00/22.66 20.96/26.38
Wilson B factor (Å2) 44.1 24.2 42.5
Average B factor (Å2) 46.9 32.0 42.5
No. non-hydrogen atoms Protein/ligand/water 2688/83/11 6433/344/512 5775/327/33
R.M.S.D.
Bond lengths (Å) 0.002 0.010 0.002
Bond angles (°) 0.451 1.064 0.412
Ramachandran analysis
Preferred regions (%) 96.12 97.82 96.83
Allowed regions (%) 3.58 2.18 3.17
Outliers (%) 0.3 0.00 0.00
Values in parentheses are for the highest resolution shell
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proteins (Fig. 3a, b). We refer herein to this more variable region
as the “speciﬁcity BG loop”, because its conformation, together
with that of the adjacent EF loop, governs accessibility of the pY
binding pocket and contributes to substrate speciﬁcity in SH2
domains42 (Fig. 3b). A particular region in the middle of the
speciﬁcity BG loop (residues 136–145) is found to be disordered
in all previously determined SOCS2 structures (PDB code, 2C9W
[https://doi.org/10.2210/pdb2C9W/pdb], 4JGH [https://doi.org/
10.2210/pdb4JGH/pdb] and 5BO4 [https://doi.org/10.2210/
pdb5BO4/pdb]) as well as our other co-crystal structures SBC-
GHR and SBC-EpoR. In this SBC-GHR2 structure, the BG loop is
in an open conformation stabilized by crystal contacts, Pro140
(BG loop) to Arg186 (SOCS box) and Pro140 (BG loop) to Ile90
(EloB), as clearly deﬁned by the unbiased omit map at this region
(Fig. 3c; Table 1).
Conformational changes of the EF and BG loop. The conﬁg-
urations of the EF and BG loops play an important role in gov-
erning the accessibility of the binding pocket and speciﬁcity
toward ligand binding42. A comparison of SOCS2 structures in
the presence and absence of peptides bound highlight con-
formational changes in EF (residue 107–116) and BG loop. In the
absence of substrate peptide, the EF loop curls up placing the
Ile110 and Cys111 at the hydrophobic SH2 domain (Fig. 4a).
Upon binding of a substrate peptide, the EF loop opens up
forming backbone interactions with GHR_pY595 (Fig. 4b), or
rearranges itself to allow a speciﬁc interaction with EpoR_pY426
(Fig. 4c). This speciﬁc interaction between EF loop and
EpoR_pY426 involves hydrophobic interactions between Ile109
and Val112 of SOCS2, Val112 of a SOCS2 symmetry mate, and
Pro(+5) of EpoR_pY426, resulting in a differential binding mode
EloBEloC
SH2
domain
SOCS box
SOCS2
Phe(–2)
Ser(–3)
Glu(–1)
pTyr(0)
Thr(+1)
Ile(+2)
Asp(+4)
Pro(+5)
Leu(+3)
Arg96
Arg73
Thr83
Ser75
Ser76
Asn94
Glu(–1)
pTyr(0)
Thr(+1)
Ile(+2)
Leu(+3)
Asp107
Arg96
Thr93
Ile(+2)
Leu(+3)
Pro(+5)
Thr(+1)
Asp(+4)
a b
c d
e
Fig. 1 Structural and interaction detail of the SBC-EpoR co-crystal. a Domain and subunit arrangement of the SBC-EpoR co-crystal. Protein chains are shown
in cartoon, with EloB (cyan), EloC (magenta) and SOCS2, comprising of SOCS box (yellow) and SH2 domain (green). The EpoR_pY426 peptide is shown in
orange stick. b The Fo-Fc ligand omit map of the EpoR_pY426 peptide (green mesh) contoured at 2.0 σ level to highlight densities for the EpoR_pY426
peptide (orange stick). c Hydrogen bond interactions (dash) between the pY of EpoR_pY426 peptide (orange stick) and SOCS2 residues (green stick).
d Hydrogen bond interaction (dash) between the EpoR_pY426 peptide (orange stick), SOCS2 (green stick) and water (red sphere). e Hydrophobic
interaction between EpoR_pY426 peptide (orange stick) and SOCS2 (surface). Hydrophobic residues on SOCS2 are colored in pink
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between EpoR_pY426 and GHR_pY595 to SOCS2. The BG loop
of SOCS2 is observed in an open conformation in the SBC-GHR2
structure whilst it is disordered in SBC-EpoR. A superimposition
of the two substrate complex structures suggest that the BG loop
opens up further in the SBC-GHR structure to accommodate two
GHR peptides (Fig. 4d).
Biophysical characterization of speciﬁcity between
GHR_pY595 and SOCS2. To evaluate the speciﬁcity of the
protein–peptide interaction in solution, we designed single-point
mutations on the peptide ﬁrst, and compared their binding to
wild-type peptide by two orthogonal biophysical methods: a direct
binding assay using SPR (SBC immobilized on the chip) and 19F
ligand-observed displacement NMR assays. In the 19F NMR dis-
placement assay, the ﬂuorine signal of a purposely-designed
reporter ligand (also referred to as spy molecule) was monitored as
a mean to quantify the extent of the competition between the
tested peptides and the spy molecule. A Carr-Purcell-Meiboom-
Gill (CPMG) pulse sequence was applied to estimate the spin–spin
relaxation time (T2) of the spy molecule in the absence and
presence of protein43–45. By adding competitor to disrupt the
protein-spy interaction, the binding afﬁnity of a competitor can be
calculated based on the degree of displacement of the spy46,47.
The spy molecule used in our assay is compound 3, a ﬂuorinated
pY analog that speciﬁcally binds to the pY pocket with a KD of
50 μM (Supplementary Fig. 4). The two assays were found to be
robust and reliable, as the measured KD (SPR) and Ki
(NMR) values correlated well (R2 of 0.74) (Supplementary Fig. 5).
First, we focused on the unique interaction formed by Val(−3)
of GHR_pY595, which inserts into a small hydrophobic cavity of
Peptide A
Pro(–4)
Asn(–1)
Pro(–2)
Val (–3)
pTyr (0)
Ser(+2)Ile(+3)
Thr(+1)
His(+4)Ile(+5)
Val(+6)
Val(+6)
Ile(+5)
His(+4)
Ile(+3)
Ser(+2)
Thr(+1)
pTyr(0)
Asn(–1)
Pro(–2)
Val(–3)
Peptide B
Val148
Ile110 Ile109 Asp107 Arg96
Ala90
Leu150
Asn94
Thr93
Peptide A
Peptide B
His149
His(+4)
Ile(+3)
Ile(+5)
Ile(+3)
Ile(+5)
Ile(+5)
Thr(+1)
Val(–3)
Pro(–2)
BG loop
EF loop
αA
αB
βBβCβDβE
Peptide APeptide B
a b
c d
e f
Fig. 2 Structural and interaction detail of the SBC-GHR co-crystal structure. Two copies of GHR_pY595 were observed in the co-crystal. One copy is shown
as peptide A (yellow stick) and the other one as peptide B (cyan stick). a The Fo-Fc ligand omit map of the peptides (green mesh) contoured at 2.5 σ level
to highlight densities for the peptide A and peptide B. b Cartoon diagram of the SH2 domain of SOCS2 (green) with peptides A and B bound. c Hydrogen
bond interactions (dash) among peptide A, peptide B, SOCS2 residues (green stick) and water (red sphere). d, e Hydrophobic interaction of the peptides
with C-terminal half and N-terminal half of the SH2 domain (surface), respectively. SOCS2 residues involved in hydrophobic interactions are colored in
pink. f The coordination of cobalt ion (pink sphere) with His149 of SOCS2 (green), His(+4) of peptide B and water molecules (red sphere)
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SOCS2 (Fig. 2e). This interaction was investigated by mutating
Val(−3) in the GHR peptide to Tyr and Arg, as representative
bulky and charged residues, respectively. We hypothesized this
structural change would disrupt the ﬁt at this small hydrophobic
pocket. Mutant V(−3)R exhibited between a 6-fold and a 14-fold
loss of binding afﬁnity to SBC, depending on the assay, suggesting
the charged group strongly disrupts the interaction (Table 2). By
contrast, the V(−3)Y was less disruptive, with only a two-fold loss
in afﬁnity.
Next, to map the relative importance and contribution of each
individual amino acids to the binding afﬁnity with SBC, alanine
scan of the substrate peptides was invoked. The peptide sequences
were designed such that individual amino acids were separately
mutated into alanine except pY, which is known to abolish
binding if mutated even to unphosphorylated Y31. The resulting
library comprised of the original wild-type sequences, ten
derivatives from GHR_pY595 and nine from EpoR_pY426, and
was characterized in parallel using SPR and 19F NMR competi-
tion assay (Table 2). Alanine substitution at pY(−3), pY(−1), pY
(+3), and pY(+4) of the GHR_pY595 resulted in at least two-fold
weakened binding (increase in KD) compared to the wild-type. In
contrast, a similar (at least two-fold) weakening in binding
afﬁnity was observed in the EpoR_pY426 peptide upon alanine
substitution at pY(−1), pY(+2), and pY(+3). These results are
consistent with observations from our crystal structures that
peptide-SOCS2 binding is mediated by hydrophobic interaction
including pY(−3), pY(+3), and pY(+5) on the GHR_pY595 and
pY(+2) and pY(+3) on the EpoR_pY426. The binding afﬁnity for
each peptide also dropped by at least two-fold with the Thr/Ala
substitution at pY(−1) position, indicating the importance of the
residue just upstream of pY.
SNPs study. Several single nucleotide polymorphisms (SNPs) on
SOCS2 are reported in the Catalog of Somatic Mutation in
Cancer database (COSMIC) as potentially linked to cancers such
as tumors of the lung, breast, and pancreas48. We thus next
decided to characterize the interaction of selected SNP SOCS2
mutants with substrate peptides GHR_pY595, EpoR_pY426 and
GHR_pY487 by SPR (Table 3). Inspection of our SBC co-crystal
structures guided us to select ﬁve known SNPs: N94D, R96L,
and R96Q that are located in the pY-pocket and involved in direct
recognition of pY; L106V that is located in the hydrophobic patch
of the SOCS2 SH2 domain that is involved in substrate interac-
tion; and C133Y that participates in the SH2 hydrophobic core
(Fig. 5a). All mutant proteins expressed and puriﬁed similarly to
wild-type, and the mutations did not appear to affect the struc-
tural integrity and solubility of the constructs, as observed by 1H
NMR (Supplementary Fig. 6).
Extended SH2 SH2 domain
αESS
33 95
96 143
144 198
αA
αB
βA βB βC
EF loop BG loop
SOCS box
H1 H2 H3
Conservation BAD GOOD
EF loop
(107–116)
Conserved
BG loop
(149–162) Lys136
Asn145
βD βE βF
βG
Specificity BG loop
(134–148)
a
b c
Fig. 3 The BG loop of SOCS2. a Secondary structure elements in SOCS2 are shown above the sequence alignment, numbering of residue is for SOCS2.
SOCS proteins with crystal structures available were aligned using T-Coffee expresso mode for sequence alignment with structural information87.
b Locations of the EF loop (orange) and the BG loop (green) on SOCS2 (white) crystal structure with bound GHR peptides A and B (cyan and yellow,
respectively). c The Fo-Fc omit map of the previously disordered region of the BG loop (green mesh) contoured at 1.5 σ level
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The L106V and C133Y mutations did not affect binding
afﬁnities compared to wild-type (Table 3). In contrast, the N94D
and R96L mutations drastically impaired substrate binding,
leading to almost undetectable binding response by SPR. Because
of the low signal-to-noise, reliable KD values could not be
measured with these protein mutants. For the R96Q mutation no
signal response was detected, suggesting that binding was
completely abolished and highlighting the most disruptive of
the mutations studied herein. Our result is consistent with
evidence by Rupp et al. that the point mutation R96C abrogates
substrate binding by SOCS249.
In addition to SPR, we evaluated to what extent SNP mutants
retain competence to bind substrate pY by monitoring the
transverse relaxation rate (R2) of spy molecule 3 using 19F NMR
EF loop
Cys111
Ile110
BG loop (disordered) EF loop
BG loop
Pro(+5)
Val112
Val112
Ile109
BG loop
a b
c d
EF loop
Fig. 4 Conformational changes of the EF and BG loops. a The EF loop curls up in the apo SOCS2 structure (white, PDB code: 2C9W), placing Ile110 and
Cys111 (stick) at the SH2 hydrophobic pocket. b The EF loop makes backbone interactions with GHR peptide (pink) in the SBC-GHR2 structure (green).
c The Ile109 and Val 112 of SOCS2 (cyan) and Val112 of SOCS2 symmetry mate (white) make unique hydrophobic interaction with Pro(+5) of EpoR
peptide (blue). d Superposition of SOCS2 from SBC-GHR2 (green) and SBC-EpoR (cyan) displays conformational changes of the BG and EF loops
Table 2 Afﬁnity measurements for GHR_pY595 and
EpoR_pY426 wild-type and mutant peptides binding to SBC
Sequence Peptide SPR KD (μM) NMR Ki (μM)
PVPDpYTSIHIV GHR wild-type 1.5 ± 0.09 1.5 ± 0.06
PRPDpYTSIHIV V(−3)R 9.0 ± 1.05 20.6 ± 2.09
PYPDpYTSIHIV V(−3)Y 3.3 ± 0.13 3.3 ± 0.24
AVPDpYTSIHIV pY(−4) 1.7 ± 0.14 0.9 ± 0.17
PAPDpYTSIHIV pY(−3) 2.7 ± 0.19 3.4 ± 0.25
PVADpYTSIHIV pY(−2) 1.4 ± 0.12 4.1 ± 0.75
PVPApYTSIHIV pY(−1) 6.2 ± 0.37 21.7 ± 3.34
PVPDpYASIHIV pY(+1) 1.0 ± 0.09 0.5 ± 0.07
PVPDpYTAIHIV pY(+2) 1.4 ± 0.07 1.2 ± 0.06
PVPDpYTSAHIV pY(+3) 3.7 ± 0.22 3.4 ± 0.66
PVPDpYTSIAIV pY(+4) 6.7 ± 0.78 18.5 ± 2.67
PVPDpYTSIHAV pY(+5) 2.4 ± 0.13 1.4 ± 0.36
PVPDpYTSIHIA pY(+6) 1.9 ± 0.09 1.6 ± 0.21
ASFEpYTILDPS EpoR wild-type 13.3 ± 0.59 7.1 ± 1.01
AAFEpYTILDPS pY(−3) 14.2 ± 0.65 7.5 ± 1.04
ASAEpYTILDPS pY(−2) 16.3 ± 1.02 7.2 ± 0.42
ASFApYTILDPS pY(−1) 21.7 ± 1.49 23.5 ± 2.99
ASFEpYAILDPS pY(+1) 17.1 ± 0.38 10.3 ± 1.28
ASFEpYTALDPS pY(+2) 30.8 ± 1.24 17.2 ± 0.89
ASFEpYTIADPS pY(+3) 32.3 ± 1.42 20.4 ± 0.88
ASFEpYTILAPS pY(+4) 18.0 ± 0.91 14.1 ± 1.74
ASFEpYTILDAS pY(+5) 8.9 ± 1.25 6.9 ± 1.39
ASFEpYTILDPA pY(+6) 16.4 ± 0.29 11.3 ± 1.29
Values reported are the means ± s.e.m. from four independent experiments
Table 3 SPR dissociation constants KD (μM) of substrate
peptides for SNP mutants of SOCS2
Protein GHR_pY595 GHR_pY487 EpoR_pY426
Wild-type 1.4 ± 0.12 5.1 ± 0.77 12.5 ± 0.63
L106V 2.4 ± 0.11 8.9 ± 0.70 14.1 ± 1.23
C133Y 2.2 ± 0.10 7.7 ± 0.71 13.4 ± 0.82
N94D Weak Weak n.d.
R96L Weak Weak n.d.
R96Q n.d. n.d. n.d.
Values reported are the means ± s.e.m. from four independent experiments
Weak: signal detected but saturation was not achieved
n.d.: signal not detected
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spectroscopy (Fig. 5b and Supplementary Fig. 7). Spy molecule 3
exhibited R2 values of 3 s−1 when free in solution, while its R2
increased to 11 s−1 in the presence of wild-type SBC, providing a
good assay window. The R2 values were comparable to wild-type
in the presence of L106V and C133Y SBC mutants (10 s−1 and
14 s−1, respectively), indicating that these mutations retain pY
recognition. In contrast, mutations on N94 and R96 led to R2
values for spy molecule 3 comparable to those in the absence of
protein (around 3–4 s−1), consistent with a loss of pY binding.
Together, the 19F NMR and the SPR data consistently elucidate
abrogated substrate binding for SOCS2 SNP mutations N94D,
R96L, R96Q, which are located around the pY pocket.
Discussion
SOCS2 is the substrate recruiting subunit of a CRL5 E3 complex
that negatively regulates the JAK-STAT signaling by targeting
substrate receptors for degradation and blocking STAT5b acti-
vation by competing with receptor pY sites. The details of these
interactions have remained elusive and to date structural infor-
mation remained limited to apo SOCS2. Herein, we have dis-
closed structures of SBC in complex with substrate peptides
EpoR_pY426 and GHR_pY595. Both peptides recapitulate a
canonical substrate-binding mode to the SH2 domain of SOCS2.
Residues at pY(−1), pY(+1) and pY (+3) positions of the
GHR_pY595 and EpoR_pY426 peptide contains similar proper-
ties; whereas residues at pY(−3), pY(+2), and pY(+5) position
are different in properties and sizes (Fig. 6a). In particular, the
Val(−3) of GHR_pY595 and Pro(+5) of EpoR_pY426 peptide
catch different hydrophobic interactions resulting in exclusive
binding modes in SOCS2 compared to the substrate peptides
bound to SOCS3 and SOCS6 (Fig. 6b, c)4,21.
The BG loop of SOCS2 had not been fully revealed in previous
published structures. Here, we report an open conformation of
the BG loop, which differs to other SOCS structures with bound
peptides, for example SOCS3:gp130 and SOCS6:c-kit19,21. In the
SOCS3 and SOCS6 peptide-bound structures, the BG loop folds
up as a hairpin interacting with the substrate peptide, forming a
triple-stranded β sheet structure (Supplementary Fig. 8a, b). The
corresponding BG loop region in SOCS2 is either fully disordered
or in an open conformation (SBC-EpoR and SBC-GHR2), sug-
gesting that this region does not participate in substrate recog-
nition. Nevertheless, interestingly, a similar triple-stranded β
sheet structure is observed in the SBC-GHR2 structure, where the
peptide B replaces the ﬁrst β-sheet of the BG loop and makes
backbone interactions with the BG loop and peptide A (Supple-
mentary Fig. 8c). A tyrosine phosphatase SHP-2, which contains
SH2 domains, features a comparable structure50. Its BG loop folds
up as a hairpin and forms a triple-stranded β sheet interaction
with two bound peptides (Supplementary Fig. 8d). Although the
canonical phosphotyrosine binding site is conserved for both
SOCS2 and SHP2, the positioning of the non-canonical phos-
photyrosine varies signiﬁcantly. The distance between Cα atoms
of phosphotyrosines within the bound peptides are 23 Å and 13 Å
in SBC-GHR and SHP2-substrate co-structures, respectively
(Supplementary Fig. 8e). Longer distance between the canonical
and non-canonical pY enable antiparallel beta strand interactions
between four amino acids of GHR peptides unlike antiparallel
interactions between two amino acids in SHP-2 substrate pep-
tides. Furthermore, a longer EF loop in SOCS2 pushes the two
GHR peptide away from itself towards the open BG loop,
enabling β sheet formation.
The BG loop along with the EF loop forms a hydrophobic
channel in SOCS3 and SOCS6. This channel imparts speciﬁcity
and restricts the binding of substrates. In contrast the open
conformation of BG loop in SOCS2 appears to be critical in
enabling SOCS2 to accommodate a wider range of substrates
including GHR, EpoR, SOCS1, and SOCS3 amongst others. A
comparison of buried surface area of the substrate peptides
among SOCS proteins, reveal that EpoR and GHR bind with
SOCS2 with only 595 Å2 and 641 Å2, respectively, in contrast
to areas of 1714 Å2 for SOCS6/c-KIT and 1761 Å2 for SOCS3/
gp130 complexes. Unlike SOCS3 and SOCS6 complex struc-
tures, the pY ﬂanking residues from EpoR and GHR do not
participate in extensive side-chain hydrogen bonding interac-
tions. Together, these observations are consistent with greater
binding afﬁnities of SOCS3 and SOCS6 substrates compared to
SOCS2 substrates. The lower binding afﬁnity for SOCS2 sub-
strates could contribute to its relatively greater promiscuity to
multiple substrates.
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Fig. 5 Position and characterization of SNPs of SOCS2. a Sequence conservation mapped onto the SH2 domain of SOCS2 (shown as surface). Conservation
surface representation based upon the ClustalW multiple sequence alignment of CIS and SOCS1–SOCS7 sequences where highly conserved residues are
shown in red/orange color and variable residue positions colored white/gold. Positions of SNP mutations are highlighted. b Transverse relaxation rates (R2)
of spy molecule 3 binding to SBC protein variants. The R2 relaxation rates were obtained by ﬁtting as exponential decay the 19F peak integrals of 3
measured at ﬁve CPMG delays in a sample in the absence or presence of SBC protein (see Supplementary Fig. 7). Error bars reﬂect the quality of the ﬁt
between the non-linear least-square curve and the experimental data
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The observation of the dual-peptide binding mode to SOCS2
was unexpected, however is not unprecedented with SH2
domains, as reported previously with the tyrosine phosphatase
SHP-250. In the co-crystal structure of SHP-2:pY peptide solved
by Zhang et al., one pY of the peptide is recognized at the pY
pocket and the other one is solvent exposed as in our structures
described herein50. Besides, two peptides run antiparallel to each
other and form an antiparallel four-stranded β sheet with the BG
loop (Supplementary Fig. 8d). Zhang et al. suggested that the
dimerization of peptide binding in SHP-2 requires at least one pY
containing peptide and leads to enhanced binding afﬁnity. In the
case of the SBC-GHR complex, despite preparing several
protein–peptide samples for co-crystallization at 1:1 molar ratio,
all dataset collected from crystals were consistent with a 1:2
(protein–peptide) binding mode. In both cases, the binding of the
non-canonical binding peptide relies on hydrophobic interaction
with the SH2 domain hydrophobic core, and backbone to back-
bone interaction with the canonical binding peptide and protein
(Fig. 6d). The 1:1 binding mode for EpoR could be justiﬁed by the
presence of Pro(+5) in EpoR, that acts as a strand breaker and
prevents backbone to backbone interaction with the second
peptide. Indeed, from the alanine scan (Table 2), we observe that
when Pro(+5) is replaced by alanine, the afﬁnity improves—
implying the possibility of secondary peptide binding.
We put forth two distinct models that might explain the dual
peptide recognition mode and its role in speciﬁc tuning of GHR
signaling response. First, a “cis” recognition mode, where the
GHR tail folds back as a hairpin structure presenting two binding
epitopes around distinct phosphorylation sites (e.g., pY487 and
pY595) for recognition (Fig. 7a). However, the crystallography
data from our follow-up experiment as described in the SBC-
GHR2 structure is not consistent with this hypothesis, as two
instances of the pY595 peptide were found bound despite a molar
ratio of 1:1 for pY487 and pY595 peptides being present in the co-
crystallization buffer. However, we cannot exclude that simulta-
neous recognition of the two distinct epitopes would require a
loop of the same tail twisting back onto itself to enhance the
binding afﬁnity of second epitope. Alternatively, we envisage a
“trans” recognition mode, where SOCS2 recognizes two separate
receptor tails of the activated dimerized GHR receptors at the cell
membrane (Fig. 7b). SOCS2 might additionally play a role as
scaffold bringing two substrates in close proximity, for example
by recruiting one instance of phosphorylated substrate to assist
the binding of un-phosphorylated one for post-translational
modiﬁcation. This mechanism evokes potential similarities with
some phosphodegrons which require two sites to be phosphory-
lated, utilizing a ﬁrst kinase to “prime” phosphorylation events,
followed by a second kinase for follow-on phosphorylation51. An
example of such a mechanism is the β-catenin degradation
mediated by the β-TrCP52. Further biophysical investigation is
warranted to address the extent to which these potential
mechanisms might be invoked for SOCS2 function.
SOCS2 is an attractive therapeutic target due to its links to
cancer, diabetes, neurological and inﬂammatory diseases23,24,53–57.
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Fig. 6 Comparison of the GHR and EpoR binding. a Overlay of the GHR_pY595 (yellow) and EpoR (orange) peptides as bound to SOCS2. Side chains circled
in blue have similar properties and red have different properties. b Different hydrophobic interactions (pink) caught by GHR_pY595 (yellow) and EpoR
(orange) peptide. c Overlay of the substrate peptide of SOCS proteins. The GHR_pY595 (yellow) and EpoR (orange) peptides catch distinct hydrophobic
cavities (pink) on SOCS2. These interactions differentiate SOCS2 substrate binding mode from other substrates of SOCS proteins. The SOCS3 substrate
peptide gp130 is in cyan (PDB ID: 2HMH) and SOCS6 substrate peptide c-Kit is in green (PDB ID: 2VIF). d The binding of the non-canonical GHR (cyan)
relies on backbone to backbone interaction and hydrophobic interaction from pY(+3) and pY(+5) of the GHR_pY595 to the SH2 domain hydrophobic core
(pink). The binding mode of EpoR (orange) makes it unfavorable to establish these interactions
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Breast, lung, liver, and ovarian cancer have been correlated with
downregulation in SOCS258–63. In addition to the JAK-STAT
pathway, a recent study has identiﬁed the involvement of SOCS2 in
the NF-κB (nuclear factor kappa-light-chain-enhancer of activated
B cells) pathway that regulates the immune and inﬂammatory
responses64,65. NF-κB is found to be constitutively activated in
many types of cancer and inﬂuences a diverse array of pro-
tumorigenic functions, therefore NK-κB plays a pivotal role in
cancer initiation and progression66. SOCS2 negatively regulates
TNFα induced NF-κB activation by targeting NDR1, a serine-
threonine kinase, for proteasomal degradation. Hence SOCS2
deﬁciency may lead to increased levels of NDR1, which results in
aggressive behavior of PC3 prostate cancer cells64. These evidences
highlight the potential in targeting SOCS2 for drug discovery for
inﬂammation and cancer biology. We have revealed structural
insights into the SOCS2-peptide interactions by X-ray crystal-
lography and identiﬁed hotspot using alanine scanning, mutation
study and SNPs study. This information provides a template to
guide the structure-based rational design of SOCS2 ligands that are
instrumental in the development of novel chemical tools to probe
SOCS2 biology, and in the quest for novel small molecule ligands
binding to SOCS2 as potential therapeutics. SOCS2 binders at the
pY binding pocket can be used as inhibitors of the CRL5SOCS2,
which would be expected to prevent degradation of target substrate
receptors, thus prolonging the activity of cytokine signaling path-
way and upregulating expression of endogenous STAT5b-
responsive gene expression. In a distinct application, a SOCS2
binder could provide a novel E3 ligase ligand for designing new
chemical degraders to hijack SOCS2 CRL activity and trigger the
degradation of unwanted proteins inside cell67–69. This approach,
also known as proteolysis targeting chimeras (PROTACs), offers the
advantage of inducing rapid and selective intracellular depletion of
the target protein, as opposed to mere blockade of a single inter-
action or activity, which pairs more closely to genetic target vali-
dation and often results in greater maximal efﬁcacy of intervention
in a signaling pathway. PROTAC-mediated protein degradation has
been shown to occur at very low compound concentration (pM to
nM range), well below the range of inhibitory concentrations for the
hijacked E3 ligase70,71. PROTACs potentially allows targeting of
intractable protein targets that are beyond the reach of conventional
small-molecule approaches that require full occupancy of a target
binding site e.g., receptor antagonists and enzyme inhibitors. A
limited set of E3 ligases have been targeted so far for PROTACs,
notably VHL70,71 and cereblon72,73, so extending the approach to
other ligandable E3 ligases would be an important advance to the
ﬁeld. The usage of SOCS2 binders for PROTACs may be speciﬁc to
SOCS2 expressing cells, thus could provide an additional layer of
tissue speciﬁc degradation of target proteins. For exam-
ple, PROTACs designed using SOCS2 binders as recruiters would
be ideal for degrading targets speciﬁcally in cells affected with
leukemia and gastrointestinal sarcoma which have been reported to
have upregulated SOCS2 expression74. Low levels of SOCS2 in
other normal tissues would help minimize toxicity. On the other
hand, a pan-SOCS recruiting PROTACs would help diversifying the
target tissue range. Our peptide-bound co-crystal structures suggest
that SOCS2 might be ligandable and provide a blueprint for the
rational structure-guided design of novel SOCS2 inhibitors and
SOCS2 ligands for PROTACs.
Methods
Cloning and protein expression. The human SOCS2 (amino acids 32–198)
and the ElonginB (amino acids 1–104) and ElonginC (amino acids 17–112) plas-
mids were used for protein expression as previously reported31,39. Brieﬂy, SBC
was co-expressed in E. coli BL21(DE3) from pLIC (His6-SOCS2) and pCDF
(EloBC) plasmids. Protein expression was induced with isopropyl β-d-1-
thiogalactopyranoside at 18 °C for 12 h. After cell lysis, SBC protein was found in
the soluble fraction and puriﬁed by afﬁnity chromatography using a HisTrap
column (GE Healthcare). Following tag cleavage with tobacco etch virus (TEV)
protease and a second HisTrap column the desired untagged protein eluted in the
ﬂow-through fractions. SBC was ﬁnally puriﬁed by size-exclusion chromatography
on a Superdex 75 16/600 column (GE Healthcare) in 25 mM HEPES, pH 7.5,
250 mM NaCl and 10 mM DTT. SOCS2 mutants N94D, R96L, R96Q, L106V or
C133Y were introduced using PCR-based site-directed mutagenesis (details of the
primers used are in Supplementary Table 1). SBC containing mutant SOCS2 were
co-expressed and puriﬁed as described above.
Crystallization and structure determination of SBC-GHR. To improve crystal-
lization, surface entropy reducing mutations were introduced into SOCS2 construct
(amino acids 32–198). Three mutation clusters (K63A/E64A/E67A; K113A and
K115A/K117A/Q118A) were identiﬁed with the SER server38. SER-assisted crys-
tallization attempts yielded crystals with the K115A/K117A/Q118A SOCS2-EloBC
(SKKQBC). Five times molar excess of GHR_pY595 (PVPDpYTSIHIV-amide,
5 mg ml−1) was incubated with SKKQBC, followed by removing unbound peptide
using a protein concentrator. Sample was concentrated to 22 mgml−1 with an
additional 0.1 M of sodium cacodylate pH7.2 added to the sample. Diffraction-
quality crystals were obtained with 0.005 M Cobalt (ll) chloride, 0.1 M MES pH 6.5,
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Fig. 7 Two models of SOCS2-substrate receptor recruitment. a Illustration of a “cis” recognition where the two binding sites on the same molecule
of GHR, pY487 and pY595, fold into a hairpin structure for SOCS2 binding. SOCS2 is shown in white surface, the hairpin structure is illustrated by
connecting the two peptides (yellow cartoon) with a red dashed line. b Illustration of a “trans” recognition where SOCS2 recruits two molecules
of receptor tails (cyan and yellow dashed lines) simultaneously after dimerization of the receptor at the membrane
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-10190-4
10 NATURE COMMUNICATIONS |         (2019) 10:2534 | https://doi.org/10.1038/s41467-019-10190-4 | www.nature.com/naturecommunications
1.0 M ammonium sulfate at 4 °C using hanging drop vapor diffusion method at 2:1
protein:precipitant ratio. Crystals were cryo-protected using 20% MPD prior to
vitriﬁcation in liquid nitrogen.
Diffraction data were collected at 100 K at Diamond Light Source beamline i04
using Pilatus 6M-F detector at 0.98 Å wavelength. Indexing and integration was
processed by XDS75 and scaling and merging with AIMLESS within the CCP4
program suite76,77. The experimental phases were obtained by identifying the
positions of arsenic atoms on the surface of SBC39, using MR-SAD phases in the
PHENIX software suite78,79. The structure was reconstructed by AutoBuild80,81
and manually built in Coot82. The resulting structure was reﬁned iteratively with
REFMAC583.
Crystallization and structure determination of SBC-EpoR. Five times molar
excess of EpoR_pY426 (ASFEpYTILDPS-amide) was incubated with SKKQBC
(5 mgml−1). Unbound peptide was removed by a protein concentrator (sartorius
Vivaspin) while the mixture was concentrated to 20 mgml−1 concentration.
Sodium cacodylate pH7.2 was added to a ﬁnal concentration of 0.1 M prior to
crystallization. Crystallization drops were set up in a ratio of 1:1 protein:precipitant
in 18% ethanol, 0.1 M HEPES pH7.5, 0.1 M MgCl2 using hanging drop at 4 °C.
Crystals were cryo-protected using 20 % PEG400 prior to ﬂash-cooled.
Diffraction data were collected at 100 K on beamline i24 at Diamond Light
Source. Data were recorded to Pilatus3 6M-F detector at 0.97 Å wavelength. Data
were indexed, integrated, and reduced using XDS75 and AIMLESS76,77. The phase
was obtained by molecular replacement (MR) using Phaser79 with the coordinates
of SOCS2-EloB-EloC (PDB ID: 2C9W) as a search model. The presence of the
EpoR_pY426 was observed in the initial electron density map. Model building was
conducted manually with Coot82 and reﬁned with cycles of retrained reﬁnement
with REFMAC583.
Crystallization and structure determination of SBC-GHR2. GHR_pY595
(PVPDpYTSIHIV-amide) and GHR_pY487 (NIDFpYAQVSDI-amide) were
mixed with SKKQBC at 1:1:1 stoichiometric ratio with a ﬁnal concentration of
20 mgml−1 and additional 0.1 M sodium cacodylate pH 7.2. Drops of the complex
were mixed 2:1 with 0.005 M cobalt chloride, 0.1 M MES pH6.5 and 1.0 M
ammonium sulfate in the sitting-drop vapor diffusion format at 4 °C. 20% MPD
was applied to crystal before ﬂash-cooling.
Data collection of the SBC-GHR2 co-crystal was at 100 K on beamline i24 at
Diamond Light Source. Images were indexed, intergraded, and reduced using
XDS75 and AIMLESS76,77. A molecular replacement solution was obtained by
Phaser79 using SBC-GHR as search model. Reﬁnement was performed using
REFMAC583 and model building was performed in COOT82.
Synthetic details. All chemicals, unless otherwise stated were commercially
available and used without further puriﬁcation. Solvents were anhydrous and
reactions preformed under positive pressure of nitrogen. Flash column chroma-
tography was performed using a Teledyne Isco Combiﬂash Rf or Rf200i. As pre-
packed columns RediSep Rf Normal Phase Disposable Columns were used. NMR
spectra were recorded on a Bruker 500 Ultrashield. 13C spectra were 1H decoupled.
Chemical shifts (δ) are reported in ppm relative to solvent (CD3OD: δH= 3.31
ppm, δC= 49.0 ppm) as internal standard. High Resolution Mass Spectra (HRMS)
were recorded on a Bruker microTOF. Low resolution MS and analytical HPLC
traces (LC-MS) were recorded on an Agilent Technologies 1200 series HPLC
connected to an Agilent Technologies 6130 quadrupole LC/MS, connected to an
Agilent diode array detector. The column used was a Waters XBridge column
(50 mm × 2.1 mm, 3.5 µm particle size) and the compounds were eluted with a
gradient of 5−95% acetonitrile/water +0.1% formic acid over 3 min. Preparative
HPLC was performed on a Gilson Preparative HPLC System with a Waters X-
Bridge C18 column (100 mm × 19 mm; 5 µm particle size) and a gradient of 5% to
95% acetonitrile in water over 10 min, ﬂow 25 ml min−1, with 0.1% formic acid in
the aqueous phase.
Cbz-O-bis(dimethylamino)phosphono)-L-tyrosine (1). O-bis(dimethylamino)
phosphono)-L-tyrosine84 (485 mg, 1.54 mmol) and NaHCO3 (260 mg, 3.1 mmol)
were dissolved in the mixture THF/H2O= 1:1 (10 ml) and N-(benzylox-
ycarbonyloxy)succinimide (383 mg, 1.54 mmol) was added. The reaction mixture
was stirred at room temperature overnight. After the addition of 5% NaHSO4 the
product was extracted with ethyl acetate, washed with brine, dried over MgSO4,
and concentrated by rotary evaporation under reduced pressure. After drying, Cbz-
O-bis(dimethylamino)phosphono)-L-tyrosine 1 (620 mg, 89%) was obtained as pale
yellow. 1H NMR (CD3OD): 2.69 (d, J= 10.1 Hz, 12H), 2.92 (dd, J= 14.0, 9.3 Hz,
1H), 3.18 (dd, J= 14.0, 4.9 Hz, 1H), 4.40 (dd, J= 4.9, 9.3 Hz, 1H), 5.03 (s, 2H), 7.06
(d, J= 8.5 Hz, 2H), 7.21 (d, J= 8.5 Hz, 2H), 7.25–7.36 (m, 5H). 31P NMR
(CD3OD): 18.2. LC-MS (m/z): [M+H]+ calcd. for C21H29N3O6P, 450.17;
found, 450.2.
Compound 2. To a mixture of the compound 1 (160 mg, 0.35 mmol), HATU
(135 mg, 0.35 mmol), HOAt (48 mg, 0.35 mmol) and DIPEA (150 µl, 1 mmol) in
DMF (1 ml), 2 M methylamine solution in THF (0.5 ml) was added under stirring
at room temperature. After 2 h, LC-MS analysis showed complete conversion of the
starting material and formation of the desired product. The mixture was diluted
with ethyl acetate, washed with 5% NaHSO4, brine, dried over MgSO4, and con-
centrated by rotary evaporation under reduced pressure. The crude product was
dissolved in the mixture ethanol/ethyl acetate= 1:1 (8 ml). Hydrogenation was
carried out using H-Cube at 80 ˚C, Pd/C, 1 atm, at 1 ml min−1. The solvent was
evaporated under vacuum to afford 2 (108 mg, 92%) which was directly used in the
next step without any further puriﬁcation. 1H NMR (CD3OD): 2.66 (s, 3H), 2.71
(d, J= 10.1 Hz, 12H), 2.81 (m, 1H), 2.96 (m, 1H), 3.51 (m, 1H), 7.09 (dd, J= 8.5,
1.0 Hz, 2H), 7.20 (d, J= 8.5 Hz, 2H). 31P NMR (CD3OD): 18.3. LC-MS (m/z):
[M+H]+ calcd. for C14H26N4O3P, 329.17; found, 329.2.
Spy molecule 3. A solution of the compound 2 (80 mg, 0.24 mmol) and DIPEA
(85 µl, 0.48 mmol) in DCM (2 ml) was cooled to −78 °C, and triﬂuoroacetic
anhydride (34 µl, 0.24 mmol) was added. The reaction mixture was stirred 1 h at
−78 °C. After solvent evaporation the residue was dissolved in acetonitrile (0.5 ml)
and 2M HCl was added (2 ml). The mixture was stirred at room temperature
overnight until no presence of the starting materials was detected by LC-MS. The
solvents were evaporated and residue was puriﬁed by HPLC to afford compound 3
(30 mg, 34%) as a white solid. 1H NMR (CD3OD): 2.69 (s, 3H), 2.96 (dd, J= 13.8,
6.4 Hz, 1H), 3.15 (dd, J= 13.8, 6.4 Hz, 1H), 4.57 (dd, J= 8.8, 6.4 Hz, 1H), 7.13 (dd,
J= 8.5, 1.1 Hz, 2H), 7.22 (d, J= 8.5 Hz, 2H). 13C NMR (CD3OD): 26.3, 37.8, 56.5,
117.3 (q, J= 286.7 Hz), 121.3 (d, J= 4.5 Hz), 131.3, 134.1, 151.9 (d, J= 6.8 Hz),
158.7 (q, J= 37.5 Hz), 172.4. 31P NMR (CD3OD): 3.7. 19F NMR (CD3OD): −75.6.
HRMS (m/z): [M+H]+ calcd. for C12H15F3N2O6P, 371.0620; found, 371.0599.
Peptide synthesis. All peptides were prepared via solid-phase peptide synthesis on
10 mmol scale using standard Fmoc chemistry on Rink amide resin (0.68 mmol g−1)
on an INTAVIS ResPepSL automated peptide synthesizer. O-(dibenzylphosphono)-
N-Fmoc-L-tyrosine was synthesized as described below. The peptides were cleaved
with 2.5% triisopropylsilane and 2.5% water in TFA. The crude peptides were
isolated from the cleavage mixture by precipitation with cold ether, dissolved in the
mixture water/DMF= 1/1 and puriﬁed by preparative HPLC under the following
conditions: Waters X-Bridge C18 column (100mm× 19mm; 5 µm particle size),
gradient of 5–95% acetonitrile in water over 10min, ﬂow 25mLmin−1, with 0.1%
formic acid in the aqueous phase, UV detection at λobs= 190 and 210 nm. The
poorly there soluble peptides were puriﬁed according to literature procedure85: the
impurities were extracted by DCM from the solution of peptides in 20% acetic acid.
The purity and identity of the peptides were determined by the analytical LCMS on
an Agilent Technologies 1200 series HPLC connected to an Agilent Technologies
6130 quadrupole LC/MS linked to an Agilent diode array detector (raw data shown
in Supplementary Fig. 9).
O-(dibenzylphosphono)-N-Fmoc-L-tyrosine. To a solution of Fmoc-tyrosine (2 g,
5 mmol) in anhydrous THF (12 ml) N-methylmorpholine (540 µl, 5 mmol) and
tert-butyldimethylsilyl chloride (740 mg, 4.9 mmol) were added. After 15 min 4,5-
dicyanoimidazole (1.8 g, 15 mmol) and diisopropylphosphoramidite (3.4 ml,
10 mmol) were added and the reaction mixture was stirred at room temperature for
4 h. After cooling to 0 °C 70% tert-butyl hydroperoxide (2 ml, 15 mmol) was
introduced. After stirring for 2 h at 0 °C, 10% Na2S2O5 (20 ml) was added and
stirring continued for one more hour. The product was extracted with ethyl acetate,
washed with a 5% solution of KHSO4, brine, dried over MgSO4, concentrated by
rotary evaporation under reduced pressure, and further puriﬁed by column
chromatography on silica gel using a gradient elution of 0–10% of MeOH in DCM
to afford O-(dibenzylphosphono)-N-Fmoc-L-tyrosine (3 g, 90%) as a pale yellow
solid. NMR spectra were in agreement with the published data86.
Isothermal titration calorimetry. Experiments were performed with ITC200
instrument (Malvern) in 100 mM HEPES pH 7.5, 50 mM NaCl, 0.5 mM TCEP at
298 K stirring the sample at 750 rpm. The ITC titration consisted of 0.4 μl initial
injection (discarded during data analysis) followed by 19 of 2 μl injections at 120 s
interval between injections. The GHR_pY595 peptide (PVPDpYTSIHIV-amide,
750 μM), EpoR_pY426 (ASFEpYTILDPS-amide, 750/1500 μM) and GHR_pY487
(NIDFpYAQVSDI-amide, 1500 μM) were directly titrated into SBC (50 μM).
Binding data was subtracted from a control titration where peptide was titrated
into buffer, and ﬁtted using a one-set-of-site binding model to obtain dissociation
constants, binding enthalpy (ΔH), and stoichiometry (N) using MicroCal ITC-
ORIGIN Analysis Software 7.0 (Malvern).
Surface plasmon resonance. Experiments were performed using Biacore T200
instrument (GH Healthcare) in 20 mM HEPES pH7.5, 150 mM NaCl, 1 mM TCEP,
0.005% Tween20 buffer at 10 °C. Biotinylated wild-type SBC and mutants were
immobilized onto a chip surface and injected a series of seven concentrations (0.08,
0.25, 0.7, 2.2, 6.7, 20 and 60 μM) of peptide across the sensor surface for 60 s
contact time and 120 sec dissociation time at 30 μl min−1 ﬂow rate. Data analysis
was carried out using Biacore Evaluation Software (GE Healthcare). All data were
double-referenced for reference surface and blank injection. The processed sen-
sograms were ﬁt to a steady-state afﬁnity using a 1:1 binding model for KD esti-
mation (raw data shown in Supplementary Figs. 10–15).
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19F CPMG NMR spectroscopy. All NMR experiments were conducted using AV-
500 MHz Bruker spectrometer equipped with a 5 mm CPQCI 1H/19F/13C/15N/D
Z-GRD cryoprobe) at 298 K. Spectra were recorded using 80 scans of a CPMG
pulse sequence that attenuates broad resonances. A CPMG delay of 0.133 s was
used, to maximize the difference between the signal intensity of spy molecule alone
and in the presence of protein (Supplementary Fig. 7). The transmitter frequency
was placed close to the resonance of O1=−35451 Hz (−75.3 ppm). Protein was
used at 5 μM and spy molecule 3 was used at 100 μM in buffer containing 20 mM
HEPES pH 8, 50 mM NaCl, 1 mM DTT, 20% D2O. The GHR related peptides
including wild-type, V(−3)R, V(−3)Y and alanine scanning peptides were used at
10 μM, whereas the EpoR related peptide including wild-type and alanine scanning
were used at 50 μM. All NMR data were processed and analyzed using TopSpin
(Bruker).
The dissociation constant of peptides (Ki) was calculated by adapting the
method described by Wang et al.47 Brieﬂy, peptides’ Ki values were obtained from
the equation below:
Ki ¼
ð½P0  ½PI  ½PLÞð½I0  ½PIÞ
½PI ð1Þ
where [I0] and [P0] are the total concentrations of the competitor (peptide
inhibitor) and protein, respectively, used in the experiment, while [PI] and [PL] are
the free concentrations of protein–peptide and protein–spy complexes, which are
unknown.
To determine [PL] the following equation was used:
IF  II
IF  IP
¼ ½PL½PL0
ð2Þ
where IF is the measured integral of the ﬂuorine peak of the spy molecule free in
solution; IP is the integral of the same signal in the presence of protein; II is the
integral of the same signal in the presence of protein and competing peptide; and
[PL0] is the concentration of protein-spy complex in the absence of competitor,
which was calculated using the following equation:
½PL0 ¼
½P0 þ ½L0 þ KD 
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ð½P0 þ ½L0 þ KDÞ2  4½P0½L0
q
2
ð3Þ
where [L0] is the total concentrations of spy molecule used in the experiment, and
KD is the dissociation constant of the protein-spy complex (determined by
ITC). To determine [PI] the following equation was used:
½PL ¼
½P0 þ ½L0 þ KD  ½PI 
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ð½P0 þ ½L0 þ KD  ½PIÞ2  4ð½P0  ½PIÞ½L0
q
2
ð4Þ
where [PL] was determined as described above (Equation 2).
T2 relaxation measurement. Spectra were acquired for each sample of spy alone
and spy in the presence of protein (wild-type and SNP mutants) at 298 K, and
80 scans using a CPMG pulse sequence with varying relaxation delays of 0.05, 0.1,
0.2, 0.4, and 0.8 s. Protein was used at 5 μM and spy was used at 100 μM in buffer
containing 20 mM HEPES pH 8, 50 mM NaCl, 1 mM DTT, 20 % D2O. The T2
relaxation time was calculated by ﬁtting the data (Supplementary Fig. 7) as a mono
exponential decay (GraphPad Prism 6) using the equation below
I tð Þ ¼ I 0ð Þet=T2 ; ð5Þ
where I(t) is the signal intensity or integral at CPMG ﬁlter t (in seconds), I(0) is the
signal intensity when t = 0, and T2 is the time constant of decay.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The coordinates and structure factors for SBC in complex with EpoR_pY426 peptide,
GHR_pY595 peptide, and GHR2_pY595 peptide have been deposited to the Protein Data
Bank (PDB) with accession codes 6I4X, 6I5N, and 6I5J, respectively. The source data
underlying Fig. 5b; Tables 2, 3, Supplementary Figs. 1d and 4a are provided as a Source
Data ﬁle. Other data are available from the corresponding author upon reasonable
request.
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